> Shares of Nastech Pharmaceuticals took a beating yesterday after P&G failed to make a scheduled $15 million payment in 2006. The two companies are collaborating on a nasal spray for osteoporosis. Report [1]
> Today Nastech announced positive Phase I data on its insulin nasal spray. Release [2]
> Solvay and Wyeth Pharmaceuticals are touting new Phase II and III data which supports the efficacy of its antipsychotic drug bifeprunox in comparison with a placebo. Report [3]
> Tucson-based ImaRX has pulled its IPO, citing weak market conditions [4]. Report [5]
> Canada's ProMetic Life Sciences has pulled its IPO as well, saying that higher 2007 revenue will make the company worth more than it could expect from a public float. Report [6]
> Migenix has raised $11.6 million in bought-deal financing. Release [7]
And Finally... In a small number of cases, parents are using genetic screening to select embryos with defects like their own. Article [8]
Links:
[1] http://seattletimes.nwsource.com/html/businesstechnology/2003462841_webnastech05.html
[2] http://www.fiercebiotech.com/node/4833
[3] http://www.forbes.com/home/feeds/afx/2006/12/06/afx3232246.html
[4] http://www.fiercebiotech.com/story/biotech-ipos-losing-their-attraction/2006-05-15
[5] http://www.chron.com/disp/story.mpl/ap/fn/4381422.html
[6] http://today.reuters.com/news/articleinvesting.aspx?view=CN&storyID=2006-12-06T131020Z_01_N06382901_RTRIDST_0_PROMETIC-IPO.XML&rpc=66&type=qcna
[7] http://biz.yahoo.com/prnews/061206/to331.html?.v=9
[8] http://www.nytimes.com/2006/12/05/health/05essa.html?ref=health